Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCH014
MIFTS: 62

Schistosomiasis

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Schistosomiasis

About this section

MalaCards integrated aliases for Schistosomiasis:

Name: Schistosomiasis 12 77 54 56 45 15 17 74 3
Katayama Fever 54 74
Bilharzia 54 3
Schistosoma Mansoni Infection 54
Schistosomiasis Mansoni 74
Blood Fluke 54

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1395
ICD9CM 36 120.8
MeSH 45 D012552
Sources

Summaries for Schistosomiasis

About this section
NIH Rare Diseases : 54 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species.  Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel.

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Praziquantel and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, spleen and skin, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

CDC : 3  

Wikipedia : 77 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Sources

Related Diseases for Schistosomiasis

About this section

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 497)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 34.4 IL13 IL4 IL5
2 urinary schistosomiasis 34.2 IFNG IL13 IL4 IL5 RNASE3
3 cytokine deficiency 30.9 IL13 IL5
4 appendicitis 30.9 ALB IL10 TNF
5 fascioliasis 30.7 ALB GPT IFNG IL10
6 strongyloidiasis 30.7 IFNG IL13 IL5
7 portal hypertension 30.6 ALB F2 GPT TNF
8 salmonellosis 30.5 ALB IFNG IFNGR1
9 endomyocardial fibrosis 30.5 IL10 IL4 TNF
10 hepatitis b 30.4 ALB F2 GPT IFNG TNF
11 paragonimiasis 30.4 IL13 IL5 RNASE3
12 plasmodium falciparum malaria 30.3 IFNG IL10 TNF
13 liver disease 30.3 ALB F2 GPT TNF
14 liver cirrhosis 30.3 ALB F2 GPT SERPINF2
15 filarial elephantiasis 30.3 IL10 IL4 IL5
16 toxoplasmosis 30.2 CD40LG IFNG IL10 IL4 TNF
17 hypersplenism 30.2 ALB F2 IFNG
18 cholecystitis 30.1 ALB F2 GPT
19 eosinophilic pneumonia 30.1 IL13 IL5 RNASE3
20 viral hepatitis 30.1 ALB F2 GPT TNF
21 neuritis 30.0 IFNG IL4 TNF
22 echinococcosis 30.0 IFNG IL10 IL5 TNF
23 hypereosinophilic syndrome 30.0 IGHE IL13 IL4 IL5 RNASE3
24 hepatic coma 30.0 ALB F2 GPT
25 tropical endomyocardial fibrosis 29.9 IL10 IL4 TNF
26 onchocerciasis 29.9 IL13 IL2 IL4 IL5 RNASE3
27 filariasis 29.9 ALB IFNG IL10 IL2 IL5 TNF
28 trichuriasis 29.9 IL10 IL13 TNF
29 buruli ulcer 29.8 CD40LG IFNG IL10 IL4
30 hepatic encephalopathy 29.8 ALB F2 GPT TNF
31 poliomyelitis 29.8 IFNG IL10 IL4 TNF
32 dermatitis 29.7 IFNG IGHE IL13 IL4 IL5
33 chlamydia 29.7 IFNG IL10 IL4 TNF
34 leishmaniasis 29.7 IFNG IFNGR1 IL10 IL13 IL4 IL5
35 typhoid fever 29.7 ALB F2 IFNG IFNGR1 TNF
36 clonorchiasis 29.7 IFNG IL10 IL2 TNF
37 parasitic helminthiasis infectious disease 29.6 IL10 IL13 IL2 IL4 IL5 RNASE3
38 alcoholic liver cirrhosis 29.6 ALB F2 GSTM1
39 smallpox 29.5 IFNG IL2 TNF
40 lymphadenitis 29.5 IFNG IFNGR1 IL10 TNF
41 meningitis 29.4 ALB CCL3 IFNG IL10 TNF
42 pneumonia 29.4 CCL3 CD40LG IL10 IL13 IL5 TNF
43 mycobacterium tuberculosis 1 29.4 IFNG IFNGR1 IL10 IL4 TNF
44 lung disease 29.3 CCL3 IL10 IL13 IL5 RNASE3 TNF
45 hepatitis e 29.3 ALB CD40LG F2 GPT IFNG TNF
46 skin disease 29.3 IFNG IL10 IL13 IL4 IL5 RNASE3
47 leprosy 3 29.3 IFNG IL10 IL2 TNF
48 human immunodeficiency virus infectious disease 29.2 CCL3 IFNG IL10 IL2 TNF
49 chagas disease 29.2 CCL3 IFNG IL10 IL2 TNF
50 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.1 CD40LG IFNG IL10 IL2 IL4

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis
Sources

Symptoms & Phenotypes for Schistosomiasis

About this section

MGI Mouse Phenotypes related to Schistosomiasis:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ALB CD40LG F2 IFNG IFNGR1 IL10
2 hematopoietic system MP:0005397 10.2 CD40LG F2 IFNG IFNGR1 IL10 IL13
3 digestive/alimentary MP:0005381 10.19 ALB F2 IFNG IFNGR1 IL10 IL13
4 immune system MP:0005387 10.14 CD40LG F2 IFNG IFNGR1 IL10 IL13
5 endocrine/exocrine gland MP:0005379 10.13 ALB CD40LG IFNG IFNGR1 IL10 IL13
6 integument MP:0010771 9.97 CD40LG F2 IFNG IFNGR1 IL10 IL13
7 liver/biliary system MP:0005370 9.97 ALB IFNG IFNGR1 IL10 IL2 IL4
8 reproductive system MP:0005389 9.85 CD40LG F2 IFNG IFNGR1 IL10 IL13
9 neoplasm MP:0002006 9.8 ALB IFNG IFNGR1 IL10 IL2 IL5
10 respiratory system MP:0005388 9.56 F2 IFNG IL10 IL13 IL2 IL4
11 skeleton MP:0005390 9.32 CD40LG F2 GPT IFNG IFNGR1 IL10
Sources

Drugs & Therapeutics for Schistosomiasis

About this section

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55268-74-1 4891
2
Artemether Approved Phase 4 71963-77-4 119380 68911
3
Lumefantrine Approved Phase 4 82186-77-4 6437380
4
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
5 Artemisinine Phase 4,Phase 3
6 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Artemether, Lumefantrine Drug Combination Phase 4
9 Antimalarials Phase 4,Phase 2,Phase 3
10 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimitotic Agents Phase 4,Phase 3,Not Applicable
12 Artemisinins Phase 4,Phase 3
13 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Not Applicable
14
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
15
Iron Approved, Experimental Phase 3,Not Applicable 7439-89-6, 15438-31-0 23925 27284
16
Zinc Approved, Investigational Phase 3 7440-66-6 32051
17
Myrrh Approved Phase 3 9000-45-7
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 58-14-0 4993
19
Artesunate Approved, Investigational Phase 2, Phase 3,Phase 3 88495-63-0 5464098 6917864
20
Triclabendazole Approved, Investigational Phase 3 68786-66-3
21
Sulfadoxine Approved, Investigational Phase 3,Phase 2 2447-57-6 17134
22
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
23
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
24
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
25
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
26
Adalimumab Approved Phase 3 331731-18-1 16219006
27
Tofacitinib Approved, Investigational Phase 3 477600-75-2
28
Tranexamic Acid Approved Phase 3 1197-18-8 5526
29
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
31
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
32
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
33 Nutrients Phase 3,Not Applicable
34 Vitamin B Complex Phase 3,Phase 2
35 Trace Elements Phase 3,Not Applicable
36 Ferric Compounds Phase 3
37 Iron Supplement Phase 3,Not Applicable
38 Vitamins Phase 3,Not Applicable
39 Hematinics Phase 3
40 Micronutrients Phase 3,Not Applicable
41 Vitamin B9 Phase 3,Phase 2
42 Folate Phase 3,Phase 2
43 Hormones Phase 3,Not Applicable
44 Vaccines Phase 3,Phase 2,Phase 1
45 Immunologic Factors Phase 3,Phase 2,Phase 1
46 Sulfalene Phase 2, Phase 3
47 Antiviral Agents Phase 2, Phase 3,Phase 3
48 Anti-Infective Agents, Urinary Phase 2, Phase 3,Phase 3
49 Renal Agents Phase 2, Phase 3,Phase 3
50 Folic Acid Antagonists Phase 2, Phase 3,Phase 3

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children Completed NCT01087099 Phase 4 Albendazole
5 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
6 The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium Unknown status NCT03133832 Phase 3 Companion Tablet
7 IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
8 A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency Unknown status NCT02337569 Phase 3 NPC-02
9 Safety and Efficacy of Mirazid for Schistosomiasis Treatment Completed NCT01529710 Phase 3 Myrrh
10 Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium Completed NCT00870649 Phase 3
11 Schistosoma Haematobium Infections and Praziquantel Completed NCT01558336 Phase 3 praziquantel
12 Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis Completed NCT00510159 Phase 2, Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamin;Praziquantel
13 Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
14 Acarbose and Secondary Prevention After Coronary Stenting Completed NCT00221156 Phase 3 Acarbose
15 Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
16 A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). Completed NCT02480153 Phase 3
17 A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis Completed NCT02281552 Phase 3 Tofacitinib;Tofacitinib
18 Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan Completed NCT00661661 Phase 3 CP-690,550
19 Haemorrhage Alleviation With Tranexamic Acid- Intestinal System Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
20 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Recruiting NCT03443973 Phase 3 Gantenerumab;Placebo
21 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
22 An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Recruiting NCT03290781 Phase 3 SHP647
23 A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) Recruiting NCT03283085 Phase 3 25 mg SHP647;75 mg SHP647
24 Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Recruiting NCT03259334 Phase 3 SHP647
25 Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST Recruiting NCT02657356 Phase 3 Placebo capsules;Bardoxolone methyl capsules
26 CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Active, not recruiting NCT02670083 Phase 3 Crenezumab;Placebo
27 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
28 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Not yet recruiting NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
29 Schistosomiasis Diagnosis Using a CAA Antigen Test Not yet recruiting NCT03779347 Phase 3 Praziquantel
30 Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Not yet recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
31 L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children Not yet recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
32 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania Not yet recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
33 A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia Terminated NCT02972658 Phase 3 Lanabecestat
34 A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Terminated NCT02783573 Phase 3 Lanabecestat;Placebo
35 An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Terminated NCT02245737 Phase 2, Phase 3 Lanabecestat;Placebo
36 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
37 An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
38 Schistosoma Mansoni Morbidity in Children Aged 1-5 Years Completed NCT01901484 Phase 2 Praziquantel
39 S. Japonicum and Pregnancy Outcomes Completed NCT00486863 Phase 2 Praziquantel
40 Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions Completed NCT03041766 Phase 2 GLA-SE solution
41 Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
42 Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Completed NCT00864838 Phase 2 Acetazolamide;Brimonidine tartarate
43 A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease Recruiting NCT03518073 Phase 2 LY3303560;Placebo
44 BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. Recruiting NCT02788513 Phase 2 BI 425809 dose 1;BI 425809 dose 2;BI 425809 dose 3;BI 425809 dose 4;Placebo
45 Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Active, not recruiting NCT03799510 Phase 2 GLA-SE solution
46 A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Active, not recruiting NCT02720523 Phase 2 Placebo;ABT-494
47 Praziquantel in Children Under Age 4 Not yet recruiting NCT03640377 Phase 2 Praziquantel
48 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
49 Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis Completed NCT01512277 Phase 1
50 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: schistosomiasis

Sources

Genetic Tests for Schistosomiasis

About this section
Sources

Anatomical Context for Schistosomiasis

About this section

MalaCards organs/tissues related to Schistosomiasis:

42
Testes, Spleen, Skin, Liver, Kidney, T Cells, Colon
Sources

Publications for Schistosomiasis

About this section

Articles related to Schistosomiasis:

(show top 50) (show all 4129)
# Title Authors Year
1
A case of acute appendicitis due to intestinal schistosomiasis. ( 30555690 )
2019
2
Difficult Causality Relationship between Colorectal Cancer and Schistosomiasis. ( 30604273 )
2019
3
Biomphalaria pfeifferi Snails and Intestinal Schistosomiasis, Lake Malawi, Africa, 2017-2018. ( 30602122 )
2019
4
Intestinal Schistosomiasis: a very long-lived tropical parasite. ( 30797063 )
2019
5
Cutaneous schistosomiasis and leishmaniasis coinfection: a case report. ( 30801816 )
2019
6
Acute paraplegia due to schistosomiasis: an uncommon cause in developed countries. ( 30610737 )
2019
7
Status of Schistosomiasis Elimination in the Caribbean Region. ( 30708966 )
2019
8
Female Genital Schistosomiasis and HIV: Research urgently needed to improve understanding of the health impacts of this important co-infection. ( 30730357 )
2019
9
Knowledge, attitudes and practices with regard to schistosomiasis prevention and control: Two cross-sectional household surveys before and after a Community Dialogue intervention in Nampula province, Mozambique. ( 30730881 )
2019
10
SWOT analysis on snail control measures applied in the national schistosomiasis control programme in the People's Republic of China. ( 30732636 )
2019
11
Results of a national school-based deworming programme on soil-transmitted helminths infections and schistosomiasis in Kenya: 2012-2017. ( 30732642 )
2019
12
Elimination of Schistosomiasis Mekongi from Endemic Areas in Cambodia and the Lao People's Democratic Republic: Current Status and Plans. ( 30736431 )
2019
13
Pulmonary schistosomiasis in a young male: A case report and review of the literature. ( 30745944 )
2019
14
The C-type Lectin Receptor-Driven, Th17 Cell-Mediated Severe Pathology in Schistosomiasis: Not All Immune Responses to Helminth Parasites Are Th2 Dominated. ( 30761125 )
2019
15
Schistosomiasis infection in pre-school aged children in Uganda: a qualitative descriptive study to identify routes of exposure. ( 30764781 )
2019
16
In vitro schistosomicidal activity of tamoxifen and its effectiveness in a murine model of schistosomiasis at a single dose. ( 30798369 )
2019
17
Schistosomiasis in School Age Children in Sierra Leone After 6 Years of Mass Drug Administration With Praziquantel. ( 30809516 )
2019
18
Restaging Pulmonary Schistosomiasis. ( 30810105 )
2019
19
Asian Schistosomiasis: Current Status and Prospects for Control Leading to Elimination. ( 30813615 )
2019
20
Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. ( 30819449 )
2019
21
Correction to: The diagnosis and treatment of urogenital schistosomiasis in Italy in a retrospective cohort of immigrants from Sub-Saharan Africa. ( 30830600 )
2019
22
Comparison of Kato Katz, antibody-based ELISA and droplet digital PCR diagnosis of schistosomiasis japonica: Lessons learnt from a setting of low infection intensity. ( 30830925 )
2019
23
Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity. ( 30832614 )
2019
24
Schistosoma haematobium causing pulmonary schistosomiasis in a returning traveller. ( 30852514 )
2019
25
Multiple infection leads to backward bifurcation for a schistosomiasis model. ( 30861662 )
2019
26
Parameter estimation of modeling schistosomiasis transmission for four provinces in China. ( 30861676 )
2019
27
Schistosomiasis and HIV-1 viral load in HIV-infected outpatients with immunological failure in Tanzania: a case-control study. ( 30866830 )
2019
28
Combining Mechanochemistry and Spray Congealing for New Praziquantel Pediatric Formulations in Schistosomiasis Treatment. ( 30870971 )
2019
29
A major hurdle in the elimination of urogenital schistosomiasis revealed: Identifying key gaps in knowledge and understanding of female genital schistosomiasis within communities and local health workers. ( 30897093 )
2019
30
Correction to: In vitro schistosomicidal activity of tamoxifen and its effectiveness in a murine model of schistosomiasis at a single dose. ( 30903346 )
2019
31
Live imaging of collagen deposition during experimental hepatic schistosomiasis and recovery: a view on a dynamic process. ( 30401957 )
2019
32
Potential Biological Control of Schistosomiasis by Fishes in the Lower Senegal River Basin. ( 30479247 )
2019
33
Interaction and involvement of cellular adhesion molecules in the pathogenesis of Schistosomiasis mansoni. ( 30503821 )
2019
34
Molecular characterisation of immunological memory following homologous or heterologous challenges in the schistosomiasis vector snail, Biomphalaria glabrata. ( 30529491 )
2019
35
Prevalence and risk factors of bovine schistosomiasis in Northwestern Ethiopia. ( 30616639 )
2019
36
Elimination of Schistosoma japonicum Transmission in China: A Case of Schistosomiasis Control in the Severe Epidemic Area of Anhui Province. ( 30621070 )
2019
37
Human schistosomiasis in Benin: Countrywide evidence of Schistosoma haematobium predominance. ( 30633895 )
2019
38
WIPO Re:Search-A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis. ( 30634429 )
2019
39
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. ( 30639432 )
2019
40
Analysis of Schistosomiasis and soil-transmitted helminths mixed infections among pupils in Enugu State, Nigeria: Implications for control. ( 30648601 )
2019
41
The cost of a disease targeted for elimination in Brazil: the case of schistosomiasis mansoni. ( 30652735 )
2019
42
The epidemiology and chemotherapeutic approaches to the control of urinary schistosomiasis in school-age children (SAC): a systematic review. ( 30658583 )
2019
43
A systematic review with epidemiological update of male genital schistosomiasis (MGS): A call for integrated case management across the health system in sub-Saharan Africa. ( 30662962 )
2019
44
The diagnosis and treatment of urogenital schistosomiasis in Italy in a retrospective cohort of immigrants from Sub-Saharan Africa. ( 30666616 )
2019
45
Correction: Tendler, M., et al. Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine. Trop. Med. Infect. Dis. 2018, 3, 121. ( 30669457 )
2019
46
Multisystem imaging review of human schistosomiasis: characteristic imaging findings. ( 30682587 )
2019
47
Strongyloidiasis and schistosomiasis: lessons from migrants' data. ( 30683227 )
2019
48
Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis. ( 30683241 )
2019
49
Transmission Dynamics of Urogenital Schistosomiasis in the Rural Community of Ebonyi State, South Eastern Nigeria. ( 30693102 )
2019
50
Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents. ( 30696838 )
2019
Sources

Variations for Schistosomiasis

About this section
Sources

Expression for Schistosomiasis

About this section
Search GEO for disease gene expression data for Schistosomiasis.
Sources

Pathways for Schistosomiasis

About this section

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.08 CCL3 CD40LG IFNG IFNGR1 IGHE IL10
2
PEDF Induced Signaling 65
Show member pathways
 13.74 CCL3 CD40LG F2 IFNG IFNGR1 IL10
3
TGF-Beta Pathway 65
Show member pathways
 13.6 CCL3 F2 IFNG IFNGR1 IL10 IL13
4
Akt Signaling 65
Show member pathways
 13.45 CCL3 CD40LG IL10 IL13 IL2 IL4
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.41 CCL3 CD40LG IFNG IFNGR1 IGHE IL10
6
PAK Pathway 65
Show member pathways
 13.34 CCL3 CD40LG IL10 IL13 IL2 IL4
7
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.22 CCL3 IFNG IFNGR1 IL10 IL2 TNF
8
Pathways in cancer 38
12.91 GSTM1 IFNG IFNGR1 IL13 IL2 IL4
9
Allograft rejection 1 38
Show member pathways
 12.8 CD40LG IFNG IFNGR1 IL10 IL13 IL2
10
Immune response NFAT in immune response 23
Show member pathways
 12.68 CD40LG IFNG IFNGR1 IGHE IL10 IL2
11
Influenza A 38
Show member pathways
 12.64 IFNG IFNGR1 IL13 IL2 IL4 TNF
12
NF-kappaB Signaling 4
12.64 CD40LG IFNG IL10 IL2 IL4 TNF
13
Immune response IL-23 signaling pathway 23
Show member pathways
 12.63 F2 IFNG IL10 IL2 TNF
14
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.63 IGHE IL13 IL4 IL5 TNF
15
Th17 cell differentiation 38
Show member pathways
 12.63 IFNG IFNGR1 IL10 IL13 IL2 IL4
16
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.57 IFNG IFNGR1 IL2 IL4 TNF
17
T cell receptor signaling pathway 38
Show member pathways
 12.52 CD40LG IFNG IL10 IL2 IL4 IL5
18
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.5 IFNG IFNGR1 IL10 IL13 IL2 IL4
19
Selenium Micronutrient Network 1
Show member pathways
 12.43 ALB F2 IFNG IL2 IL4 TNF
20
IL-17 Family Signaling Pathways 66
Show member pathways
 12.4 IFNG IL13 IL4 IL5 TNF
21
Toxoplasmosis 38
Show member pathways
 12.37 CD40LG IFNG IFNGR1 IL10 IL4 TNF
22
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.36 IFNG IL10 IL13 IL2 IL4 IL5
23
Tuberculosis 38
12.27 IFNG IFNGR1 IL10 TNF
24
Bacterial infections in CF airways 23
Show member pathways
 12.23 IFNG IFNGR1 IL4 TNF
25
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.22 GAPDH IL10 IL13 TNF
26
Th1 Differentiation Pathway 66
Show member pathways
 12.15 IFNG IFNGR1 IL10 IL2 TNF
27
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 12.13 F2 IFNG IL13 IL4 TNF
28
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.13 CCL3 IFNG IFNGR1 IL10 IL13 IL2
29
Interleukin-4 and 13 signaling 67
12.08 IGHE IL10 IL13 IL4 TNF
30
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.08 IFNG IL10 IL2 IL4 IL5 TNF
31
Spinal Cord Injury 1
12.07 IFNG IL2 IL4 TNF
32
IL12-mediated signaling events 1
Show member pathways
 12.04 CCL3 IFNG IL2 IL4
33
Jak-Stat Signaling Pathway (sino) 68
11.94 IFNG IFNGR1 IL10 IL2
34
Glucocorticoid receptor regulatory network 1
11.92 IFNG IL13 IL2 IL4 IL5
35
Hematopoietic cell lineage 38
11.89 IL4 IL5 TNF
36
Amoebiasis 38
11.88 IFNG IL10 TNF
37
Rheumatoid arthritis 38
11.86 CCL3 IFNG TNF
38
Dendritic Cells Developmental Lineage Pathway 66
11.84 IFNG IL10 IL2 TNF
39
Salmonella infection (KEGG) 38
11.83 CCL3 IFNG IFNGR1
40
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.79 CD40LG IFNG IL2 IL4 IL5 TNF
41
IL4-mediated signaling events 1
11.78 CD40LG IGHE IL10 IL4 IL5
42
Lung fibrosis 1
11.77 CCL3 IL13 IL4 IL5 TNF
43
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.76 CD40LG IFNG IL2 TNF
44
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.68 IFNG IL2 TNF
45
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.65 CCL3 IFNG IL10 IL13 IL2 IL4
46
Interleukin-10 signaling 67
11.64 CCL3 IL10 IL13 IL4 TNF
47
Malaria 38
11.63 CD40LG IFNG IL10 TNF
48
Photodynamic therapy-induced AP-1 survival signaling. 1
11.6 IFNG IL2 TNF
49
Cellular Transformation by HTLV1 65
Show member pathways
 11.59 IFNG IFNGR1 TNF
50
Aryl Hydrocarbon Receptor Pathway 1
11.56 IFNG IL2 TNF
Sources

GO Terms for Schistosomiasis

About this section

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 ALB CCL3 CD40LG F2 IFNG IGHE
2 external side of plasma membrane GO:0009897 9.55 CD40LG F2 IGHE IL13 TNF
3 extracellular space GO:0005615 9.47 ALB CCL3 CD40LG F2 GPT IFNG

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.96 CCL3 IFNG LGMN TNF
2 defense response to bacterium GO:0042742 9.94 IGHE IL10 RNASE3 TNF
3 MAPK cascade GO:0000165 9.92 CCL3 IL2 IL5 TNF
4 positive regulation of protein phosphorylation GO:0001934 9.87 F2 IFNG IL2 TNF
5 inflammatory response GO:0006954 9.85 CCL3 CD40LG IL10 IL13 IL5 TNF
6 immune response GO:0006955 9.85 CCL3 CD40LG IFNG IGHE IL10 IL13
7 response to organic substance GO:0010033 9.84 IL10 SERPINF2 TNF
8 positive regulation of inflammatory response GO:0050729 9.81 CCL3 IL2 TNF
9 B cell differentiation GO:0030183 9.8 CD40LG IL10 IL4
10 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.79 F2 GAPDH RNASE3
11 positive regulation of T cell proliferation GO:0042102 9.77 CD40LG IL2 IL4
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 IL13 SERPINF2 TNF
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.69 IL10 IL13 IL4
14 cellular response to hepatocyte growth factor stimulus GO:0035729 9.67 IL10 LGMN
15 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.66 IFNG IFNGR1
16 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL2 IL5
17 positive regulation of podosome assembly GO:0071803 9.65 IL5 TNF
18 negative regulation of fibrinolysis GO:0051918 9.63 F2 SERPINF2
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IL2 IL4
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 IFNG IL13 IL2 IL4
21 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
22 positive regulation of cytokine secretion GO:0050715 9.61 GAPDH IL10 TNF
23 cytokine-mediated signaling pathway GO:0019221 9.61 CCL3 IFNGR1 IGHE IL10 IL13 IL2
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL10 IL4
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.56 IL10 TNF
26 positive regulation of B cell proliferation GO:0030890 9.56 IL13 IL2 IL4 IL5
27 regulation of immunoglobulin secretion GO:0051023 9.55 CD40LG TNF
28 regulation of isotype switching GO:0045191 9.54 IL10 IL4
29 type 2 immune response GO:0042092 9.52 IL10 IL4
30 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
32 receptor biosynthetic process GO:0032800 9.46 IL10 TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
34 regulation of signaling receptor activity GO:0010469 9.32 CCL3 CD40LG F2 IFNG IL10 IL13
35 positive regulation of cell proliferation GO:0008284 10.07 F2 IFNG IL2 IL5 LGMN
36 positive regulation of gene expression GO:0010628 10 CCL3 IFNG IL13 IL4 TNF

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 F2 IL10 IL2 IL4 IL5
2 cytokine activity GO:0005125 9.28 CCL3 CD40LG IFNG IL10 IL13 IL2
Sources

Sources for Schistosomiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....